Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.


PURPOSE Evidence supporting the clinical utility of predictive biomarkers of anthracycline activity is weak, with a recent meta-analysis failing to provide strong evidence for either HER2 or TOP2A. Having previously shown that duplication of chromosome 17 pericentromeric alpha satellite as measured with a centromere enumeration probe (CEP17) predicted… (More)
DOI: 10.1200/JCO.2013.54.7869

5 Figures and Tables



Citations per Year

104 Citations

Semantic Scholar estimates that this publication has 104 citations based on the available data.

See our FAQ for additional information.

  • Presentations referencing similar topics